Understanding Patent Process for Generics and Biosimilars in Japan
If you are planning to register a generic or biosimilar drug in Japan, it is essential to understand the country’s two-stage patent linkage system, that operates through Ministry of Health, Labor, and Welfare (MHLW) administrative notices rather than formal regulations. The First Stage ensures generic drugs do not infringe on brand patents during regulatory review.